In an effort to treat and identify Alzheimer's patients early on during the disease, the FDA says it may relax the guidelines on Alzheimer's early-stage trials. The Agency has issued a proposal designed to help researchers and developers find new treatments for patients before the onset of overt (noticeable) dementia. It is virtually impossible to enroll patients in experimental drug trials for early-stage Alzheimer's disease because of the lack of definitive biological markers for this stage of the disease, the FDA (Food and Drug Administration) explained...
More...
More...